Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

David C. Wheeler, Bergur V. Stefánsson, Niels Jongs, Glenn M. Chertow, Tom Greene, Fan Fan Hou, John J.V. McMurray, Ricardo Correa‐Rotter, Peter Rossing, Robert D. Toto, C. David Sjöström, Anna Maria Langkilde, Hiddo J.L. Heerspink